Functional analysis of the involvement of apurinic/apyrimidinic endonuclease 1 in the resistance to melphalan in multiple myeloma

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Xie, Jiayin ^a   Zhang, Liang ^a   Li, Mengxia ^a   Du, Jia ^a   Zhou, Liwei ^a   Yang, Senlin ^a   Zeng, Linli ^a   Li, Zengpeng ^a   Wang, Ge ^a   Wang, Dong ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Acquired melphalan resistance; Base excision repair; DNA repair; Human apurinic apyrimidinic endonuclease 1; Multiple myeloma

Indexed keywords

DNA (APURINIC OR APYRIMIDINIC SITE) LYASE; MELPHALAN; MULTIDRUG RESISTANCE PROTEIN 1; OLIGONUCLEOTIDE;

ACETYLATION; ARTICLE; BASE PAIRING; DNA REPAIR; EXCISION REPAIR; GEL MOBILITY SHIFT ASSAY; HUMAN; IMMUNOPRECIPITATION; MULTIPLE MYELOMA; OXIDATION REDUCTION STATE; PROTEIN FUNCTION; PROTEIN MODIFICATION; WESTERN BLOTTING;

ACETYLATION; ANTINEOPLASTIC AGENTS, ALKYLATING; CELL LINE, TUMOR; DNA REPAIR; DNA-(APURINIC OR APYRIMIDINIC SITE) LYASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MELPHALAN; MULTIPLE MYELOMA; MUTATION; OXIDATION-REDUCTION; P-GLYCOPROTEIN; RNA INTERFERENCE; TIME FACTORS; TRANSFECTION; UP-REGULATION;

EID: 84892176430     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-11     Document Type: Article

References (29)

1. Falco P, Bringhen S, Avonto I, Gay F, Morabito F, Boccadoro M, Palumbo A. Melphalan and its role in the management of patients with multiple myeloma. Expert Rev Anticancer Ther 2007, 7(7):945-957. 10.1586/14737140.7.7.945, 17627453.
2. Sanderson BJ, Shield AJ. Mutagenic damage to mammalian cells by therapeutic alkylating agents. Mutat Res 1996, 355(1-2):41-57.
3. Shekhar MP. Drug resistance: challenges to effective therapy. Curr Cancer Drug Targets 2011, 11(5):613-623. 10.2174/156800911795655921, 21486215.
4. Deffie AM, Alam T, Seneviratne C, Beenken SW, Batra JK, Shea TC, Henner WD, Goldenberg GJ. Multifactorial resistance to adriamycin: relationship of DNA repair, glutathione transferase activity, drug efflux, and P-glycoprotein in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia. Cancer Res 1988, 48(13):3595-3602.
5. Spanswick VJ, Craddock C, Sekhar M, Mahendra P, Shankaranarayana P, Hughes RG, Hochhauser D, Hartley JA. Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma. Blood 2002, 100(1):224-229. 10.1182/blood.V100.1.224, 12070031.
6. Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003, 101(6):2377-2380. 10.1182/blood-2002-06-1768, 12424198.
7. Fromme JC, Verdine GL. Base excision repair. Adv Protein Chem 2004, 69:1-41.
8. Wilson DM, Simeonov A. Small molecule inhibitors of DNA repair nuclease activities of APE1. Cell Mol Life Sci 2010, 67(21):3621-3631. 10.1007/s00018-010-0488-2, 2956791, 20809131.
9. Vascotto C, Cesaratto L, Zeef LA, Deganuto M, D'Ambrosio C, Scaloni A, Romanello M, Damante G, Taglialatela G, Delneri D, et al. Genome-wide analysis and proteomic studies reveal APE1/Ref-1 multifunctional role in mammalian cells. Proteomics 2009, 9(4):1058-1074. 10.1002/pmic.200800638, 3802553, 19180539.
10. Xanthoudakis S, Smeyne RJ, Wallace JD, Curran T. The redox/DNA repair protein, Ref-1, is essential for early embryonic development in mice. Proc Natl Acad Sci USA 1996, 93(17):8919-8923. 10.1073/pnas.93.17.8919, 38569, 8799128.
11. Zhang Y, Wang J, Xiang D, Wang D, Xin X. Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE1/Ref-1) in human ovarian cancer and indentification of the therapeutic potential of APE1/Ref-1 inhibitor. Int J Oncol 2009, 35(5):1069-1079.
12. Jiang Y, Guo C, Fishel ML, Wang ZY, Vasko MR, Kelley MR. Role of APE1 in differentiated neuroblastoma SH-SY5Y cells in response to oxidative stress: use of APE1 small molecule inhibitors to delineate APE1 functions. DNA Repair (Amst) 2009, 8(11):1273-1282. 10.1016/j.dnarep.2009.08.003, 2765866, 19726241.
13. Wang D, Xiang DB, Yang XQ, Chen LS, Li MX, Zhong ZY, Zhang YS. APE1 overexpression is associated with cisplatin resistance in non-small cell lung cancer and targeted inhibition of APE1 enhances the activity of cisplatin in A549 cells. Lung Cancer 2009, 66(3):298-304. 10.1016/j.lungcan.2009.02.019, 19324449.
14. Wang D, Luo M, Kelley MR. Human apurinic endonuclease 1 (APE1) expression and prognostic significance in osteosarcoma: enhanced sensitivity of osteosarcoma to DNA damaging agents using silencing RNA APE1 expression inhibition. Mol Cancer Ther 2004, 3(6):679-686.
15. Yang ZZ, Chen XH, Wang D. Experimental study enhancing the chemosensitivity of multiple myeloma to melphalan by using a tissue-specific APE1-silencing RNA expression vector. Clin Lymphoma Myeloma 2007, 7(4):296-304. 10.3816/CLM.2007.n.006, 17324338.
16. Deepak K, Srivastava BJVB, Rajendra Prasad J, Molina T, Beard WA, Tomkinson AE, Wilson SH. Mammalian abasic site base excision repair. Identification of the reaction sequence and rate-determining steps. J Biol Chem 1998, 273(33):21203-21209. 10.1074/jbc.273.33.21203, 9694877.
17. Evans AR, Limp-Foster M, Kelley MR. Going APE over ref-1. Mutat Res 2000, 461(2):83-108. 10.1016/S0921-8777(00)00046-X, 11018583.
18. Sengupta S, Mantha AK, Mitra S, Bhakat KK. Human AP endonuclease (APE1/Ref-1) and its acetylation regulate YB-1-p300 recruitment and RNA polymerase II loading in the drug-induced activation of multidrug resistance gene MDR1. Oncogene 2011, 30(4):482-493. 10.1038/onc.2010.435, 3010319, 20856196.
19. Kimura Y, Morita SY, Matsuo M, Ueda K. Mechanism of multidrug recognition by MDR1/ABCB1. Cancer Sci 2007, 98(9):1303-1310. 10.1111/j.1349-7006.2007.00538.x, 17608770.
20. Vascotto C, Fantini D, Romanello M, Cesaratto L, Deganuto M, Leonardi A, Radicella JP, Kelley MR, D'Ambrosio C, Scaloni A, et al. APE1/Ref-1 interacts with NPM1 within nucleoli and plays a role in the rRNA quality control process. Mol Cell Biol 2009, 29(7):1834-1854. 10.1128/MCB.01337-08, 2655621, 19188445.
21. Li MX, Wang D, Zhong ZY, Xiang DB, Li ZP, Xie JY, Yang ZZ, Jin F, Qing Y. Targeting truncated APE1 in mitochondria enhances cell survival after oxidative stress. Free Radic Biol Med 2008, 45(5):592-601. 10.1016/j.freeradbiomed.2008.05.007, 18515104.
22. Xiang DB, Chen ZT, Wang D, Li MX, Xie JY, Zhang YS, Qing Y, Li ZP, Xie J. Chimeric adenoviral vector Ad5/F35-mediated APE1 siRNA enhances sensitivity of human colorectal cancer cells to radiotherapy in vitro and in vivo. Cancer Gene Ther 2008, 15(10):625-635. 10.1038/cgt.2008.30, 18535621.
23. Guikema JE, Linehan EK, Tsuchimoto D, Nakabeppu Y, Strauss PR, Stavnezer J, Schrader CE. APE1- and APE2-dependent DNA breaks in immunoglobulin class switch recombination. J Exp Med 2007, 204(12):3017-3026. 10.1084/jem.20071289, 2118529, 18025127.
24. Masani S, Han L, Yu K. Apurinic/apyrimidinic endonuclease 1 is the essential nuclease during immunoglobulin class switch recombination. Mol Cell Biol 2013, 33(7):1468-1473. 10.1128/MCB.00026-13, 3624277, 23382073.
25. Chaney SG, Sancar A. DNA repair: enzymatic mechanisms and relevance to drug response. J Natl Cancer Inst 1996, 88(19):1346-1360. 10.1093/jnci/88.19.1346, 8827012.
26. McNeill DR, Lam W, DeWeese TL, Cheng YC, Wilson DM. Impairment of APE1 function enhances cellular sensitivity to clinically relevant alkylators and antimetabolites. Mol Cancer Res 2009, 7(6):897-906. 10.1158/1541-7786.MCR-08-0519, 2745049, 19470598.
27. Fung H, Demple B. Distinct roles of Ape1 protein in the repair of DNA damage induced by ionizing radiation or bleomycin. J Biol Chem 2011, 286(7):4968-4977. 10.1074/jbc.M110.146498, 3037609, 21081487.
28. Xie JY, Li MX, Xiang DB, Mou JH, Qing Y, Zeng LL, Yang ZZ, Guan W, Wang D. Elevated expression of APE1/Ref-1 and its regulation on IL-6 and IL-8 in bone marrow stromal cells of multiple myeloma. Clin Lymphoma Myeloma Leuk 2010, 10(5):385-393. 10.3816/CLML.2010.n.072, 21030352.
29. Kuhne A, Tzvetkov MV, Hagos Y, Lage H, Burckhardt G, Brockmoller J. Influx and efflux transport as determinants of melphalan cytotoxicity: resistance to melphalan in MDR1 overexpressing tumor cell lines. Biochem Pharmacol 2009, 78(1):45-53. 10.1016/j.bcp.2009.03.026, 19447222.